Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesReview: differences in efficacy and acceptability exist for 12 new-generation antidepressants for major depression
Evidence-Based Medicine, 10/26/09
Usherwood T – In patients with major depression, new–generation antidepressants differ in efficacy and acceptability.
Methods- Included studies were randomised controlled trials (RCTs) that compared any of 12 new–generation antidepressants (bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnaciprin, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine) as monotherapy for acute–phase treatment of major depression. Placebo groups and RCTs of postpartum depression were excluded. Outcomes were response and dropout rates at 8 weeks.
- Cochrane Collaboration Depression, Anxiety, and Neurosis Review Group’s controlled trials register (to Nov 2007) and reference lists were searched for RCTs. Pharmaceutical companies, regulatory agencies, and study investigators were contacted. 117 RCTs (n = 25 928; 64% women; 53 RCTs [n = 9321] had patients >65 y of age) were included. Mean study duration was 8 weeks (14 RCTs had >12 wks’ follow–up). 12 RCTs had adequate allocation concealment and blinding.
- When direct comparisons of antidepressants were pooled, differences existed in response rates for various comparisons.
- Direct comparisons for response favour escitalopram over citalopram; citalopram over reboxetine and paroxetine; mirtazapine over fluoxetine and venlafaxine; sertraline over fluoxetine; and venlafaxine over fluoxetine and fluvoxamine./li>
- Network meta–analysis, which included indirect comparisons, showed that escitalopram and sertraline have high efficacy and the best acceptability profile.
- Fluoxetine had fewer dropouts than reboxetine (number needed to treat [NNT] 13, 95% CI 8 to 74), and citalopram had fewer dropouts than sertraline (NNT 15, CI 9 to 255).
Related Articles
Deep brain stimulation as a new therapeutic approach in therapy-resistant mental disorders: ethical aspects of investigational treatment
European Archives of Psychiatry and Clinical Neuroscience, 11/10/09
Relevance Score: 93%
Omega-3 Augmentation of Sertraline in Treatment of Depression in Patients With Coronary Heart Disease: A Randomized Controlled Trial
JAMA, 10/22/09
Relevance Score: 93%
Major depression: the importance of clinical characteristics and treatment response to prognosis
Depression and Anxiety, 10/07/09
Relevance Score: 93%
Pharmacogenetics Studies in STARD: Strengths, Limitations, and Results
Psychiatric Services, 11/02/09
Relevance Score: 92%
Sexual Functions and Depressive Symptoms after Photodynamic Therapy for Vulvar Lichen Sclerosus in Postmenopausal Women from the Upper Silesian Region of Poland
The Journal of Sexual Medicine, 10/08/09
Relevance Score: 92%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines
Acta Neurologica Scandinavica, 11/27/09
Propylene Glycol Accumulation in Critically Ill Patients Receiving Continuous Intravenous Lorazepam Infusions
Annals of Pharmacotherapy, 11/25/09
Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial
Acta Neurologica Scandinavica, 11/25/09
Sponsor
Article Search
Sponsor